Chongqing Genrix Biopharmaceutical Co Ltd

688443

Company Profile

  • Business description

    Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

  • Contact

    No. 699, Maliu Avenue
    Area A, Building 2
    International Bio City
    Banan
    Chongqing401338
    CHN

    T: +86 2361758666

    http://www.genrixbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    743

Stocks News & Analysis

stocks

Moated ASX share crashes amid weak trading update

Bapcor signalled lower underlying profits for fiscal 2025, while an audit cast doubt on the firm’s past earnings.
stocks

A collection of our best stock opportunities

Our latest articles about where we see opportunities in the market.
stocks

Morningstar analyst reacts to Macquarie Group’s earnings

Banking Analyst Nathan Zaia’s analysis of MQG’s results.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,023.3056.600.63%
CAC 407,857.3656.480.72%
DAX 4024,217.37247.011.03%
Dow JONES (US)44,632.99204.57-0.46%
FTSE 1009,136.3254.880.60%
HKSE25,473.4051.05-0.20%
NASDAQ21,098.2980.29-0.38%
Nikkei 22540,682.147.590.02%
NZX 50 Index12,961.2824.870.19%
S&P 5006,370.8618.91-0.30%
S&P/ASX 2008,764.1059.500.68%
SSE Composite Index3,632.4122.700.63%

Market Movers